In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy.

Rogulski, K R; Freytag, S O; Zhang, K; Gilbert, J D; Paielli, D L; Kim, J H; Heise, C C; Kirn, D H

Rogulski, K R; Freytag, S O; Zhang, K; Gilbert, J D; Paielli, D L; Kim, J H; Heise, C C; Kirn, D H.

Affiliation

Rogulski KR; Department of Radiation Oncology, Henry Ford Health System, Detroit, Michigan 48202, USA.

Cancer Res ; 60(5): 1193-6, 2000 Mar 01.

Article in En | MEDLINE | ID: mdl-10728673

Subject(s)

Adenoviridae; Genes, p53; Neoadjuvant Therapy; Neoplasms/genetics; Neoplasms/therapy; Drug Resistance, Neoplasm/genetics; Gene Expression Regulation, Neoplastic; Humans; Mutation; Neoplasms/radiotherapy; Tumor Cells, Cultured

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Adenoviridae / Genes, p53 / Neoadjuvant Therapy / Neoplasms Limits: Humans Language: En Journal: Cancer Res Year: 2000 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links